Mirikizumab

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Mar 13, 2024 → Apr 1, 2028

NCT ID

NCT05509777

About Mirikizumab

Mirikizumab is a phase 3 stage product being developed by Eli Lilly for Crohn's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05509777. Target conditions include Crohn's Disease.

What happened to similar drugs?

9 of 20 similar drugs in Crohn's Disease were approved

Approved (9) Terminated (4) Active (11)

✅adalimumabAbbVieApproved

✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved

✅Infliximab + Prednisolone + AzathioprinePfizerApproved

✅Celebrex + placeboPfizerApproved

✅Cimzia + MesalamineUCBApproved

✅Certolizumab PegolUCBApproved

✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07446101	Phase 1	Recruiting	Mar 1, 2026	Feb 1, 2027	Healthy
NCT07059130	Approved	Recruiting	Jul 16, 2025	Feb 28, 2026	Crohn Disease (CD)
NCT05509777	Phase 3	Recruiting	Mar 13, 2024	Apr 1, 2028	Crohn's Disease
NCT05644353	Phase 1	Completed	Dec 5, 2022	May 25, 2023	Healthy
NCT05515601	Phase 1	Completed	Aug 31, 2022	Feb 20, 2023	Healthy
NCT04548219	Phase 1	Completed	Sep 11, 2020	Jan 11, 2021	Healthy
NCT04232553	Phase 3	Active	Jun 22, 2020	Apr 1, 2027	Crohn's Disease
NCT04004611	Phase 2	Completed	May 18, 2020	Mar 15, 2023	Ulcerative Colitis
NCT03556202	Phase 3	Terminated	Sep 3, 2018	Feb 7, 2022	Psoriasis
NCT03519945	Phase 3	Active	Jul 18, 2018	Dec 1, 2027	Ulcerative Colitis

Competing Products

20 competing products in Crohn's Disease

See all competitors

Product	Company	Stage	Hype Score
CT-P13 + Remicade	Celltrion	Phase 3	40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 1	29
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
CP-461	Astellas Pharma	Phase 2	35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg	Eisai	Phase 1/2	32
E6011 + Placebo	Eisai	Phase 2	35
E6011 + Placebo	Eisai	Phase 1	21
adalimumab + adalimumab + placebo	Eisai	Phase 2/3	38
adalimumab	Eisai	Phase 2/3	38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo	Eli Lilly	Phase 3	40
Mirikizumab + Mirikizumab + Tirzepatide + Placebo	Eli Lilly	Phase 3	47
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
Mirikizumab	Eli Lilly	Phase 3	44
Matching Placebo for Upadacitinib + Upadacitinib	AbbVie	Phase 3	40
Adalimumab + Placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo for Upadacitinib	AbbVie	Phase 3	40
Placebo + ABT-494	AbbVie	Phase 2	35
ABT-494	AbbVie	Phase 2	35
Risankizumab + Comparator	AbbVie	Pre-clinical	33
placebo for risankizumab + risankizumab IV + risankizumab SC	AbbVie	Phase 3	40